肿瘤测序替代结直肠癌Lynch综合征筛查及现有分子检测的评估
该研究纳入419例前瞻性结直肠癌病例和46例已知Lynch综合征验证病例,比较一线肿瘤测序与现有序贯检测的敏感性。肿瘤测序敏感性100%,优于IHC加BRAF(89.7%)和MSI加BRAF(91.4%),特异性相当,并可同时提供KRAS/NRAS/BRAF及DPYD信息用于治疗选择。
要点
- 一线肿瘤测序对Lynch综合征筛查敏感性100%,高于现有序贯检测。
- 肿瘤测序可同时识别KRAS/NRAS/BRAF突变和DPYD胚系突变,指导治疗。
- 肿瘤测序特异性与IHC加BRAF或MSI加BRAF相当。
核心结论
- 一线肿瘤测序比现有多重序贯检测更简单,对Lynch综合征筛查敏感性更高,并可同时提供治疗选择所需的关键信息。
研究设计与样本
- 研究纳入419例连续结直肠癌病例(前瞻性队列)和46例已知Lynch综合征病例(验证队列),均接受盲法肿瘤测序。
主要发现
- 肿瘤测序识别了验证队列全部46例已知Lynch综合征病例,并额外识别前瞻性队列中12例Lynch综合征病例。
- MSI或IHC序贯BRAF p.V600E检测分别漏检5例和6例Lynch综合征。
- 肿瘤测序识别284例KRAS、NRAS或BRAF突变可能影响IV期结直肠癌治疗,并识别8例DPYD胚系突变患者(与氟尿嘧啶化疗毒性相关)。
临床怎么用
- 可考虑将一线肿瘤测序作为结直肠癌Lynch综合征筛查的替代方案,同时获取治疗相关分子信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Universal tumor screening for Lynch syndrome (LS) in colorectal cancer (CRC) is recommended and involves up to 6 sequential tests. Somatic gene testing is performed on stage IV CRCs for treatment determination. The diagnostic workup for patients with CRC could be simplified and improved using a single up-front tumor next-generation sequencing test if it has higher sensitivity and specificity than the current screening protocol. OBJECTIVE: To determine whether up-front tumor sequencing (TS) could replace the current multiple sequential test approach for universal tumor screening for LS. DESIGN, SETTING, AND PARTICIPANTS: Tumor DNA from 419 consecutive CRC cases undergoing standard universal tumor screening and germline genetic testing when indicated as part of the multicenter, population-based Ohio Colorectal Cancer Prevention Initiative from October 2015 through February 2016 (the prospective cohort) and 46 patients with CRC known to have LS due to a germline mutation in a mismatch repair gene from January 2013 through September 2015 (the validation cohort) underwent blinded TS. MAIN OUTCOMES AND MEASURES: Sensitivity of TS compared with microsatellite instability (MSI) testing and immunohistochemical (IHC) staining for the detection of LS. RESULTS: In the 465 patients, mean age at diagnosis was 59.9 years (range, 20-96 years), and 241 (51.8%) were female. Tumor sequencing identified all 46 known LS cases from the validation cohort and an additional 12 LS cases from the 419-member prospective cohort. Testing with MSI or IHC, followed by BRAF p.V600E testing missed 5 and 6 cases of LS, respectively. Tumor sequencing alone had better sensitivity (100%; 95% CI, 93.8%-100%) than IHC plus BRAF (89.7%; 95% CI, 78.8%-96.1%; P = .04) and MSI plus BRAF (91.4%; 95% CI, 81.0%-97.1%; P = .07). Tumor sequencing had equal specificity (95.3%; 95% CI, 92.6%-97.2%) to IHC plus BRAF (94.6%; 95% CI, 91.9%-96.6%; P > .99) and MSI plus BRAF (94.8%; 95% CI, 92.2%-96.8%; P = .88). Tumor sequencing identified 284 cases with KRAS, NRAS, or BRAF mutations that could affect therapy for stage IV CRC, avoiding another test. Finally, TS identified 8 patients with germline DPYD mutations that confer toxicity to fluorouracil chemotherapy, which could also be useful for treatment selection. CONCLUSIONS AND RELEVANCE: Up-front TS in CRC is simpler and has superior sensitivity to current multitest approaches to LS screening, while simultaneously providing critical information for treatment selection.
引用
- Hampel H, Pearlman R, Beightol M, et al. Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. JAMA Oncol. 2018. PMID: 29596542. doi:10.1001/jamaoncol.2018.0104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。